Free tool
FAERS Monitor: Tobradex St
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050818 or its brand name (Tobradex St, Dexamethasone, Tobramycin). Reports on generic versions are filed under their own applications.
Reports
130
Serious
46
35% of reports
Hospitalization
23
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye pain17
- ocular hyperaemia10
- vision blurred10
- product dose omission issue9
- condition aggravated7
- headache7
- drug ineffective6
- eye irritation6
- eyelid pain5
- off label use5
- photophobia5
- anxiety4
- eye swelling4
- fall4
- infection4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 4 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 5 |
| 2018 | 7 |
| 2019 | 19 |
| 2020 | 16 |
| 2021 | 14 |
| 2022 | 1 |
| 2023 | 12 |
| 2024 | 14 |
| 2025 | 23 |
| 2026 | 4 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,029 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| eyelid painSignal | 5 | 399.1 | 168.8 | 1,604 |
| eye painSignal | 17 | 48.8 | 31.3 | 750 |
| photophobiaSignal | 5 | 43.0 | 18.2 | 165 |
| ocular hyperaemiaSignal | 10 | 34.1 | 18.8 | 290 |
| eye swellingSignal | 4 | 17.4 | 6.6 | 47 |
| eye irritationSignal | 6 | 16.9 | 7.7 | 75 |
| vision blurredSignal | 10 | 11.8 | 6.5 | 89 |
| product dose omission issueSignal | 9 | 5.0 | 2.6 | 25 |
| infectionSignal | 4 | 4.5 | 1.7 | 8 |
| condition aggravatedSignal | 7 | 3.7 | 1.8 | 12 |
| anxiety | 4 | 2.3 | 0.9 | 2 |
| fall | 4 | 1.9 | 0.7 | 1 |
| headache | 7 | 1.8 | 0.9 | 2 |
| off label use | 5 | 0.9 | 0.4 | 0 |
| drug ineffective | 6 | 0.7 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.